Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2025-05-27 eCollection Date: 2025-07-01 DOI:10.1007/s13691-025-00768-9

Takafumi Kitazono, Taichi Isobe, Satoshi Nishiyori, Wataru Kusano, Kenro Tanoue, Tomoyasu Yoshihiro, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, Kenji Tsuchihashi, Koichi Akashi, Eishi Baba

{"title":"Metastatic urachal carcinoma treated with trifluridine/tipiracil and bevacizumab: a case report.","authors":"Takafumi Kitazono, Taichi Isobe, Satoshi Nishiyori, Wataru Kusano, Kenro Tanoue, Tomoyasu Yoshihiro, Hirofumi Ohmura, Kyoko Yamaguchi, Mamoru Ito, Kenji Tsuchihashi, Koichi Akashi, Eishi Baba","doi":"10.1007/s13691-025-00768-9","DOIUrl":null,"url":null,"abstract":"<p><p>A 53-year-old man with a tumorous lesion at the bladder apex was diagnosed with an unresectable urachal carcinoma. After 10 cycles of combined therapy with 5-fluorouracil, leucovorin, and oxaliplatin, a combination of trifluridine/tipiracil and bevacizumab was initiated as second-line chemotherapy. Despite requiring a switch to bevacizumab monotherapy after the sixth cycle due to hematological toxicity, this regimen effectively controlled the disease for 16 cycles. It resulted in a progression-free survival of 17 months. To the best of our knowledge, this is the first report documenting the use of trifluridine/tipiracil and bevacizumab combination therapy for urachal carcinoma. While the observed disease control was notable in this patient, further accumulation of clinical experience and careful evaluation are warranted before generalizing the efficacy of this regimen in this rare malignancy.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 3","pages":"280-288"},"PeriodicalIF":0.5000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12229294/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Cancer Conference Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s13691-025-00768-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

A 53-year-old man with a tumorous lesion at the bladder apex was diagnosed with an unresectable urachal carcinoma. After 10 cycles of combined therapy with 5-fluorouracil, leucovorin, and oxaliplatin, a combination of trifluridine/tipiracil and bevacizumab was initiated as second-line chemotherapy. Despite requiring a switch to bevacizumab monotherapy after the sixth cycle due to hematological toxicity, this regimen effectively controlled the disease for 16 cycles. It resulted in a progression-free survival of 17 months. To the best of our knowledge, this is the first report documenting the use of trifluridine/tipiracil and bevacizumab combination therapy for urachal carcinoma. While the observed disease control was notable in this patient, further accumulation of clinical experience and careful evaluation are warranted before generalizing the efficacy of this regimen in this rare malignancy.

查看原文本刊更多论文

三氟定/替吡拉西联合贝伐单抗治疗转移性尿管癌1例

一例53岁男性膀胱顶端肿瘤病变被诊断为不可切除的尿管癌。在5-氟尿嘧啶、亚叶酸蛋白和奥沙利铂联合治疗10个周期后，开始了trifluridine/tipiracil和bevacizumab的联合二线化疗。尽管由于血液学毒性，在第6个周期后需要切换到贝伐单抗单药治疗，但该方案有效地控制了16个周期的疾病。结果无进展生存期为17个月。据我们所知，这是第一份记录使用trifluridine/tipiracil和bevacizumab联合治疗尿管癌的报告。虽然在该患者中观察到的疾病控制是显著的，但在推广该方案对这种罕见恶性肿瘤的疗效之前，需要进一步积累临床经验和仔细评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)